It is appreciated that cancer cells, including breast, prostate, and non-small cell lung cancer (NSCLC), alter their choline metabolism in relation to their state of immortalisation and oncogene addiction, with a higher expression of choline kinase α (CHKA) and, concomitantly, high concentrations of phosphocholine (PCho) and the total choline species in malignant metastatic cells compared to normal epithelial cells [2,3,4,5,6]. Here, CHKA is linked to non-small cell lung carcinoma.